Lantheus Holdings reported a significant increase in worldwide revenue in the third quarter of 2024 over the third quarter in 2023.
For the period (end-September 30) the company posted $379 million in revenue, up 18.4% from $320 million in the same period last year, citing strong sales of its F-18 DCFPyL (Pylarify) PET imaging agent for prostate cancer. Sales of Pylarify were $259.8 million for the quarter.
The company also reported an adjusted net income of $124 million, up 20.4% from $103 million in the same quarter last year. It said its operating income increased 19% to $133.7 million.
In addition, Lantheus said its cash and cash equivalents grew to $866.4 million at the end of the third quarter, compared with $713.7 million as of December 31, 2023, even after accounting for a $35 million net investment related to the acquisition of RM2 from Life Molecular and a $5 million equity investment in Radiopharm Theranostics.
![Images show the pectoralis muscles of a healthy male individual who never smoked (age, 66 years; height, 178 cm; body mass index [BMI, calculated as weight in kilograms divided by height in meters squared], 28.4; number of cigarette pack-years, 0; forced expiratory volume in 1 second [FEV1], 97.6% predicted; FEV1: forced vital capacity [FVC] ratio, 0.71; pectoralis muscle area [PMA], 59.4 cm2; pectoralis muscle volume [PMV], 764 cm3) and a male individual with a smoking history and chronic obstructive pulmonary disorder (COPD) (age, 66 years; height, 178 cm; BMI, 27.5; number of cigarette pack-years, 43.2, FEV1, 48% predicted; FEV1:FVC, 0.56; PMA, 35 cm2; PMV, 480.8 cm3) from the Canadian Cohort Obstructive Lung Disease (i.e., CanCOLD) study. The CT image is shown in the axial plane. The PMV is automatically extracted using the developed deep learning model and overlayed onto the lungs for visual clarity.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/03/genkin.25LqljVF0y.jpg?auto=format%2Ccompress&crop=focalpoint&dpr=2&fit=crop&h=167&q=70&w=250)
